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RT-PCRAbstract CDX genes are classically known as regulators of axial elongation during early embryo-
genesis. An unsuspected role for CDX genes has been revealed during hematopoietic development.
The CDX gene family member CDX2 belongs to the most frequent aberrantly expressed proto-
oncogenes in human acute leukemias and is highly leukemogenic in experimental models. We used
reversed transcriptase polymerase chain reaction (RT-PCR) to determine the expression level of
CDX2 gene in 30 pediatric patients with acute lymphoblastic leukemia (ALL) at diagnosis and
30 healthy volunteers. ALL patients were followed up to detect minimal residual disease (MRD)
on days 15 and 42 of induction. We found that CDX2 gene was expressed in 50% of patients
and not expressed in controls. Associations between gene expression and different clinical and lab-
oratory data of patients revealed no impact on different ﬁndings. With follow up, we could not con-
ﬁrm that CDX2 expression had a prognostic signiﬁcance.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.D license.Introduction
The last decade has seen large advances in our understanding
of the regulatory network in prenatal and adult hematopoiesis.As one pivotal class of regulatory factors, the highly conserved
family of homeobox genes has been identiﬁed as playing major
roles not only in normal hematopoiesis but also in leukemo-
genesis [1].
Homeobox genes are divided into 2 classes. Class I includes
clustered genes (HOX) that comprises 39 members, and the
class II divergent homeobox genes are dispersed through the
genome and include smaller families such as the MSX, Para-
Hox (CDX), PAX, DLX, and Engrailed (EN) groups [1].
CDX genes play a key role in the homeobox regulatory net-
work, acting as upstream regulators of several Hox genes [2].
CDX2 belongs to the ParaHox (CDX) cluster, which were
originally described as master regulators of embryonic body
development [3].
56 H.H. Arnaoaut et al.Of note, it was demonstrated that the N-terminal part of
CDX2 is necessary for transcriptional activation of Hox genes,
supporting the concept that activation of downstream Hox
genes is a potential key mechanism of CDX2 induced transfor-
mation [4]. Thus, perturbation of CDX2 might be linked to
critical alterations in downstream Hox genes that are central
regulators of normal early hematopoietic development in the
adult with a distinct expression proﬁle in human and murine
early progenitor cells [5].
Pediatric ALL is the most common malignancy of child-
hood, and is treated with chemotherapy alone or in combina-
tion with radiation therapy and, in selected cases, with
allogeneic stem cell transplantation. Long-term cure and sur-
vival rates have signiﬁcantly improved by adapting therapy
intensity to prognostic factors associated with disease aggres-
siveness and recurrence. Currently, the most important prog-
nostic parameter represents the early in vivo evaluation of
therapy response by measuring leukemic cell persistence after
induction therapy (minimal residual disease, MRD) [6].
We questioned whether CDX2 expression level at diagnosis
could have a role in the prognosis of pediatric ALL by analyz-
ing the association between gene expression and MRD mea-
sured on days 15 and 42 of induction.390bp
600pb
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Figure 1 (Upper part): CDX2 gene expression by RT-PCR of
some ALL patients. Lane 1 represents the molecular weight (MW)
marker (NoLimits 100 bp DNA Fragment, Fermentas Inc., Glen
Burnie, Maryland). It shows bands at MWs: 100, 200, 300, 400,
500, 600, 700, 800, 900, and 1000 bp. Lanes 2, 3, 4, 6, 7, 8 represent
CDX2 expression (band at 390 bp) in ALL positive patients. Lane
5 represents ALL patients with negative gene expression (no band
at 390 bp). (Lower part): represents GAPDH expression at 600 bp.Patients and methods
The present study was conducted on 30 newly diagnosed ALL
children. They were referred to pediatric unit of National Can-
cer Institute, Cairo University during the period from August
2011 to August 2012. The patients were treated with ALL pro-
tocol adopted from St Jude Children’s Research Hospital
(SJCRH) study. Thirty normal volunteers were enrolled as
the control group. They were enrolled from Surgery Clinic of
Children’s Hospital Cairo University. Consents were taken
from parents of children included in the study. Approval of
the research committee of the clinical and chemical pathology
department at Cairo University was obtained.
Criteria for the diagnosis of ALL were based on standard
morphology and immunophenotyping. Therefore, patients
were subjected to the following: complete history taking and
clinical examination. The following laboratory investigations
were done: complete blood picture using cell counter (cell
DYN 1700), immunophenotyping included lymphoid markers
for ALL, bone marrow aspirate and bone marrow biopsy if
indicated. Semi-quantitative RT-PCR was used to determine
the expression level of CDX2 gene for both patients and con-
trols. Genotyping for CDX2 gene expression was performed
for each child as follows: RNA was extracted from 3 ml of
whole blood collected on 1.5 mg/ml EDTA using High pure
RNA isolation kit (GeneJET RNA Puriﬁcation Kit#K0731,
Fermentas, Vilnius, Lithuania). RNA was reverse transcribed
with reverse transcriptase enzyme by incubation for 30 min
at 60 C. Following a denaturation step, the cDNA synthesis
was carried out using random hexamer primers in a total vol-
ume of 20 ll [4 ll 5X Reaction Buffer (250 mM Tris–HCl, pH
8.3), 250 mM KCl, 20 mM MgCl2, 50 mM DTT), 1 ll Ribo-
Lock RNase Inhibitor (20 l/ll), 2 ll 10 mM dNTP Mix,
2 ll M-MuLV Reverse Transcriptase (20 l/ll), 1 ll hexapri-
mer (100 lM, 0.2 lg/ll), 2 lg RNA]. Subsequently, the cDNA
was heated to inactivate the reverse transcriptase enzyme and
was stored at 20 C until used for PCR ampliﬁcation.CDX2 gene expression was determined following the protocol
of Eda et al. [7]. The following primer sequences were used:
For CDX2 gene sense: (50-CGGCTGGAGCTGGAGAAG
G-30) and antisense:(50-TCAGCCTGGAATTGCTCTGC-30)
and for GAPDH (as an internal control): sense: (50-CCACCC
ATGGCAAATTCCATGGCA-30), antisense: (50-TCTAGAC
GGCAGGTCAGGTCCACC-30). The PCR was performed
in 25 lL of specimen containing approximately 50 ng of
cDNA, 2 lL of 2.5 mM of each of the deoxyribonucleotide tri-
phosphates (dNTPs), 0.5 lL of 25 mM MgCl2, 10 pmol of
both primers and 0.5 U Taq polymerase.
Ampliﬁcation of cDNA for CDX2 gene was done for 35 cy-
cles of denaturation at 94 C for 30 s, annealing at 60 C for
30 s, extension at 72 C for 1 min and ﬁnal extension at
72 C for 7 min. Ampliﬁcation of cDNA for GAPDH gene
was done for 35 cycles of denaturation at 94 C for 30 s,
annealing at 64 C for 30 s, extension at 72 C for 1 min.
The PCR products were separated by electrophoresis on
2% agarose gel stained with ethidium bromide. The size of
the ampliﬁed product was read with the use of a DNA marker
of different molecular weights (Ladder) (NoLimits 100 bp
DNA Fragment, Fermentas Inc., Glen Burnie, Maryland).
The sample was considered positive when a clear, sharp, dis-
tinct band was observed at the speciﬁc molecular weight
390 bp for CDX2 and 600 bp for GAPDH.
Fig. 1 shows results of CDX2 and GAPDH genes expres-
sion by RT-PCR of some ALL patients.
Statistics
Comparison of quantitative variables between the study
groups was done using non para metrical Mann–Whitney
test. For comparing categorical data, Chi square (v2) test
was performed. Exact test was used instead when the ex-
pected frequency is less than 5. A probability value (p value)
Table 2 Summary of laboratory data of the 30 ALL patients
at diagnosis.
Item Median (range)
WBCs · 103/ll 19.3 (3–114.7)
Hemoglobin g/dl 9.0 (3.3–11.8)
Platelets 103 (17–565)
PB blasts% 69.5 (14–94)
BM blasts% 87 (40–96)
WBCs, white blood cell count; PB, peripheral blood; BM, bone
marrow.
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tistical calculations were done using SPSS (Statistical Package
for the Social Science; SPSS Inc., Chicago, IL, USA) version
16.
Results
The present study included 30 pediatric ALL patients. The age
of patients ranged from 2 to 15 years, with a median value of 6.
They were 20 males (66.7%), 10 females (33.3%) with male to
female ratio of 2:1. Thirty normal volunteers were enrolled as
the control group. Their age ranged from 3 to 14 years, with a
median value of 8. They were 19 males (63.3%), 11 females
(36.7%) with male to female ratio of 1.7:1.
Table 1 presents a summary of clinical presentation of the
ALL patients.
Table 2 presents a summary of laboratory data of the ALL
patients at diagnosis.
Immunophenotyping was done and it was found that 6/30
(20%) of patients had Pro-B phenotyping, 16/30 (53.3%)
Pre-B, 5/30 (16.7%) C-ALL and 3/30 (10%) had early T
ALL phenotyping.
Analysis of CDX2 expression revealed that 15/30 (50%) of
patients had positive gene expression and 15/30 (50%) had
negative expression.
Table 3 shows a comparison of laboratory data regarding
gene expression in the patient group and we did not ﬁnd signif-
icant association between CDX2 gene expression among ALL
cases and their clinical and laboratory ﬁndings except for PB
blasts which were signiﬁcantly higher among patients with neg-
ative gene expression (p value = 0.04).
All patients were followed up for detection of MRD on
days 15 and 42 of induction. MRD was detected by ﬂowcytom-
etry. We found that all patients showed positive MRD at day
15. On day 42, 50% of patients showed positive MRD and
50% converted to negative. We compared ALL patients with
positive and negative MRD on day 42 regarding different clin-Table 1 Summary of clinical presentation of the 30 ALL
patients.
Parameter No. (30) Percentage (%)
Sex
Male 20 66.7
Female 10 33.3
Lymphadenopathy
Present 23 76.7
Absent 7 23.3
Splenomegaly
Present 27 90
Absent 3 10
Hepatomegaly
Present 26 86.7
Absent 4 13.3
Fever
Present 26 86.7
Absent 4 13.3
Pallor
Present 30 100.0ical and laboratory ﬁndings but we did not ﬁnd any signiﬁcant
differences. Among patients with positive MRD on day 42, we
observed that 60% of them had positive gene expression and
40% had negative gene expression without signiﬁcance (p
value = 0.273).
Discussion
The CDX gene family member CDX2 belongs to the most fre-
quent aberrantly expressed proto-oncogenes in human acute
leukemias and is highly leukemogenic in experimental models.
Correlative studies indicate that CDX2 functions as a master
regulator of perturbed HOX gene expression in human acute
myeloid leukemia, locating this ParaHox gene at a central po-
sition for initiating and maintaining HOX gene dysregulation
as a driving leukemogenic force [1].
Here we determined CDX2 gene expression and explored
its prognostic impact on the clinical course of pediatric ALL
by analyzing a cohort of 30 children with ALL as well as 30
controls. In our study, CDX2 gene was not expressed among
the control group but was found among 50% of patients (p
value < 0.001).
In comparison to other results, HY etal., in 2011 found that
positive expression rate of CDX2 gene in de novo ALL pa-
tients was 60.8% [8]. Also, Riedt etal studied CDX2 gene
expression and their results revealed negative or very low
CDX2 expression of healthy donor BM, PB, and puriﬁed B
(CD19+), T (CD3+), or natural killer (NK; CD56+) cells,
however, they found that aberrant CDX2 protein was con-
ﬁrmed in primary samples collected from patients with pediat-
ric ALL (78%) and that mononuclear cells collected from
patients presenting with AML expressed CDX2 in 9 of 10 cases
(90%) [9].
On the other hand, Li Y.X and coworkers in 2011 investi-
gated the expression of CDX2 gene in pediatric patients with
acute leukemia by RT-PCR and its clinical implication. Their
results showed positive expression of CDX2 in 20 of 21 ALL
cases (95.2%) and in 5 of 9 AML cases (55.6%). However,
no expression of CDX2 was observed in all normal controls
in agreement with our results which also revealed a signiﬁcant
difference between patient and normal control groups [10].
Our results showed lower percentage of CDX2 gene expres-
sion among leukemic patients compared to previous studies
and this might be explained by ethnic difference and small
number of studied groups which may require further detailed
analysis on a broader scale.
Our study showed no signiﬁcant associations between
CDX2 gene expression and different clinical and laboratory
Table 3 Comparison of laboratory data in relation to CDX2 gene expression in 30 ALL patients at diagnosis.
Item Positive gene expression (N= 15) Negative Gene expression (N= 15) P value
Median (range) Median (range)
Age (years) 6 (2.5–13) 8 (2–15) 0.150
DNA index 1.2 (1–1.4) 1.1 (1–1.3) 0.324
TLC · 103/ll 16.4 (3–77) 25 (13–114.7) 0.060
Hb g/dl 8.9 (3.3–11.8) 9.3 (4.6–11.7) 0.800
Platelets 130 (17–565) 51(20–550) 0.340
Blasts in PB% 48 (14–90) 78 (33–94) 0.040
Blasts in BMA% 85 (20–96) 87 (61–95) 0.450
The DNA index (DI) is a prognostic factor in childhood ALL. The accuracy of DI measurement is important for risk stratiﬁcation: hyper-
diploidy with DI > or = 1.16 is predictive of low risk whereas hypodiploidy is associated with high risk. DI measured by ﬂow cytometry, TLC,
total leukocytic count; Hb, hemoglobin; PLTs, platelets; PB, peripheral blood; BMA, bone marrow aspirate; SD, standard deviation.
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this gene on diagnostic ALL ﬁndings.
It has been reported that CDX2 is aberrantly expressed in
>80% of human AML patients [1]. Scholl et al. reported
the highest expression of CDX2 in patients with t(9;11) fol-
lowed by normal karyotype AML and t(15;17) positive
patients [11]. Previous results showed that CDX2 is aberrantly
expressed in nearly all cases of AML and promotes leukemo-
genesis, whereas CDX2 expression is absent in normal hemato-
poietic stem and progenitor cells [12].
So far the leukemogenic potential of CDX2 has been linked
to its ability to deregulate HOX gene expression: it has been
shown that CDX2 is able to upregulate expression of 50 located
Hox genes known to be leukemogenic and that this ability de-
pends on its N-terminal transactivation domain [12]. However,
it is unclear whether CDX2 can also exert its oncogenic effect
by other pathways. This might be particularly true in adult
patients with ALL, in which HOX gene deregulation is compa-
rably rare compared with AML [13]. This could indicate that
in ALL the leukemogenic effect of CDX2 does not depend
on HOX gene perturbation to the same extent as in AML,
and that CDX2 mediates its oncogenic potential through dif-
ferent gene networks in ALL. Taken together, these data link
aberrant expression of CDX2 to myeloid as well as lymphoid
leukemia. So far it is unknown whether the stage of differenti-
ation of the cell, which is initially hit by aberrant CDX2
expression, determines the phenotype of the leukemia.
We further analyzed the impact of CDX2 expression level
on the prognosis through following up the patients to detect
MRD on days 15 and 42 of induction. We found that all pa-
tients had positive MRD on day 15 and 50% was converted
to negative MRD on day 42. Among patients with positive
MRD on day 42, we observed that 60% of them had positive
gene expression and 40% had negative gene expression with-
out signiﬁcance (p value = 0.273).
Other studies signiﬁcantly correlated the expression level of
CDX2 in patients with ALL with the prognosis and treatment
outcome (high expression levels were associated with inferior
overall survival) of the analyzed patients and they concluded
that it might be useful as a risk stratiﬁcation marker in patients
with pediatric ALL [9,14].
Analysis of larger cohorts of patients should further
support the validity of this association and determine whether
patients with CDX2 expression would beneﬁt from alterations
of current treatment protocols.Conclusion
Our ﬁndings together with other studies raise the possibility
that CDX2 gene may contribute to the molecular ‘‘environ-
ment’’ need to acquire and propagate leukemic growth.
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